Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122466) titled 'Efficacy and safety of Henagliflozin in lowering serum uric acid levels in patients with hyperuricemia: a prospective randomized double-blind controlled study' on April 14.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shanghai Tenth People's Hospital
Condition:
Hyperuricemia
Intervention:
Control group:Placebo, once a day
Recruitment Status: Recruiting
Phase: New Treatment Measure Clinical Study
Date of First Enrollment: 2025-02-12
Target Sample Size: Control group:109;Experimental group:109;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.c...